OBJECTIVE: This analysis was performed to investigate the hypothesis that ulceration predicts improved response to adjuvant interferon (IFN) therapy. SUMMARY BACKGROUND DATA: Several studies have demonstrated that adjuvant therapy for high-risk melanoma patients with IFN alfa-2b improves disease-free survival (DFS), although the impact on overall survival (OS) is controversial. Recent data have suggested that IFN therapy may preferentially benefit patients with ulcerated primary melanomas. METHODS: Post hoc analysis was performed by a prospective multi-institutional randomized study of observation versus adjuvant IFN therapy for melanoma. All patients underwent sentinel lymph node biopsy; completion lymphadenectomy was performed for patients with sentinel lymph node metastasis. Patients were stratified by Breslow thickness, ulceration, and nodal status. Kaplan-Meier analysis of DFS and OS was performed and included univariate and multivariate analyses. RESULTS: A total of 1769 patients were analyzed (1311 without ulceration, 458 with ulceration) with a median follow-up of 71 months. Ulceration was associated with significantly worse DFS and OS in both node-negative and node-positive patients. Kaplan-Meier analysis of node-negative and node-positive patients by ulceration status revealed that the only significant impact of interferon was improved DFS in the ulcerated node-positive patients (P = 0.0169). IFN therapy had no significant impact on OS regardless of ulceration status, however. On multivariate analysis, IFN treatment was a significant independent predictor of DFS among ulcerated patients (odds ratio, 0.51; 95% confidence interval, 0.30-0.83; P = 0.0053), but not among patients without ulceration. CONCLUSIONS: These data support the conclusion that ulceration is a predictive marker for response to adjuvant IFN therapy. Future studies to evaluate specifically the differential effect of IFN on patients with ulcerated melanomas may allow us to focus this therapy on patients most likely to benefit from it.
RCT Entities:
OBJECTIVE: This analysis was performed to investigate the hypothesis that ulceration predicts improved response to adjuvant interferon (IFN) therapy. SUMMARY BACKGROUND DATA: Several studies have demonstrated that adjuvant therapy for high-risk melanomapatients with IFN alfa-2b improves disease-free survival (DFS), although the impact on overall survival (OS) is controversial. Recent data have suggested that IFN therapy may preferentially benefit patients with ulcerated primary melanomas. METHODS: Post hoc analysis was performed by a prospective multi-institutional randomized study of observation versus adjuvant IFN therapy for melanoma. All patients underwent sentinel lymph node biopsy; completion lymphadenectomy was performed for patients with sentinel lymph node metastasis. Patients were stratified by Breslow thickness, ulceration, and nodal status. Kaplan-Meier analysis of DFS and OS was performed and included univariate and multivariate analyses. RESULTS: A total of 1769 patients were analyzed (1311 without ulceration, 458 with ulceration) with a median follow-up of 71 months. Ulceration was associated with significantly worse DFS and OS in both node-negative and node-positive patients. Kaplan-Meier analysis of node-negative and node-positive patients by ulceration status revealed that the only significant impact of interferon was improved DFS in the ulcerated node-positive patients (P = 0.0169). IFN therapy had no significant impact on OS regardless of ulceration status, however. On multivariate analysis, IFN treatment was a significant independent predictor of DFS among ulceratedpatients (odds ratio, 0.51; 95% confidence interval, 0.30-0.83; P = 0.0053), but not among patients without ulceration. CONCLUSIONS: These data support the conclusion that ulceration is a predictive marker for response to adjuvant IFN therapy. Future studies to evaluate specifically the differential effect of IFN on patients with ulcerated melanomas may allow us to focus this therapy on patients most likely to benefit from it.
Authors: Ellen H de Moll; Yichun Fu; Yingzhi Qian; Sara H Perkins; Shira Wieder; Sacha Gnjatic; Romain Remark; Sebastian G Bernardo; Marina Moskalenko; Jonathan Yao; Tammie Ferringer; Rui Chang; Jerry Chipuk; Basil A Horst; Miriam B Birge; Robert G Phelps; Yvonne M Saenger Journal: Cancer Immunol Immunother Date: 2015-06-16 Impact factor: 6.968
Authors: Kelly M McMasters; Michael E Egger; Michael J Edwards; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; Robert C G Martin; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; B Scott Davidson; Jeffrey E Gershenwald; Lee J Hagendoorn; Arnold J Stromberg; Charles R Scoggins Journal: J Clin Oncol Date: 2016-02-08 Impact factor: 44.544
Authors: Paolo A Ascierto; Antonio M Grimaldi; Nicolas Acquavella; Lorenzo Borgognoni; Luana Calabrò; Natale Cascinelli; Alessandra Cesano; Michele Del Vecchio; Alexander M Eggermont; Mark Faries; Soldano Ferrone; Bernard A Fox; Thomas F Gajewski; Jérôme Galon; Sacha Gnjatic; Helen Gogas; Mohammed Kashani-Sabet; Howard L Kaufman; James Larkin; Roger S Lo; Alberto Mantovani; Kim Margolin; Cornelis Melief; Grant McArthur; Giuseppe Palmieri; Igor Puzanov; Antoni Ribas; Barbara Seliger; Jeff Sosman; Peter Suenaert; Ahmad A Tarhini; Giorgio Trinchieri; Fernando Vidal-Vanaclocha; Ena Wang; Gennaro Ciliberto; Nicola Mozzillo; Francesco M Marincola; Magdalena Thurin Journal: J Transl Med Date: 2013-06-03 Impact factor: 5.531
Authors: Vladimir Bezrookove; David De Semir; Mehdi Nosrati; Schuyler Tong; Clayton Wu; Suresh Thummala; Altaf A Dar; Stanley P L Leong; James E Cleaver; Richard W Sagebiel; James R Miller; Mohammed Kashani-Sabet Journal: J Invest Dermatol Date: 2013-09-04 Impact factor: 8.551